Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck. 2012;34:877–85. https://doi.org/10.1002/hed.21830.
Bishop JA, Guo TW, Smith DF, Wang H, Ogawa T, Pai SI, et al. Human papillomavirus-related carcinomas of the sinonasal tract. Am J Surg Pathol. 2013;37:185–92. https://doi.org/10.1097/PAS.0b013e3182698673.
McKay SP, Grégoire L, Lonardo F, Reidy P, Mathog RH, Lancaster WD. Human papillomavirus (HPV) transcripts in malignant inverted papilloma are from integrated HPV DNA. Laryngoscope. 2005;115:1428–31. https://doi.org/10.1097/01.mlg.0000168091.50584.b4.
D’Abramo CM, Archambault J. Small molecule inhibitors of human papillomavirus protein - protein interactions. Open Virol J. 2011;5:80–95. https://doi.org/10.2174/1874357901105010080.
• Elgart K, Faden DL. Sinonasal squamous cell carcinoma: etiology, pathogenesis, and the role of human papilloma virus. Curr Otorhinolaryngol Rep. 2020;8:111–9. https://doi.org/10.1007/s40136-020-00279-6. This recent review provides a comprehensive overview of contemporary insight into the role of HPV in SNSCC and highlights gaps in the understanding of this relationship.
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35. https://doi.org/10.1056/NEJMoa0912217.
Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261–9. https://doi.org/10.1093/jnci/djn011.
Evans M, Newcombe R, Fiander A, Powell J, Rolles M, Thavaraj S, et al. Human papillomavirus-associated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK population. BMC Cancer. 2013;13:220. https://doi.org/10.1186/1471-2407-13-220.
Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011;22:1071–7. https://doi.org/10.1093/annonc/mdr006.
•• Chang Sing Pang KJ, Mur T, Collins L, Rao SR, Faden DL. Human papillomavirus in sinonasal squamous cell carcinoma: a systematic review and meta-analysis. Cancers (Basel) 2020;13:45. https://doi.org/10.3390/cancers13010045. This meta-analysis includes a large cohort of SNSCC patients and focuses on limitations to current HPV detection methods, proposes a mechanism for HPV reaching the sinonasal cavity, and draws comparisons between HPV epidemiology in SNSCC and OPSCC.
Syrjänen S, Puranen M. Human papillomavirus infections in children: the potential role of maternal transmission. Crit Rev Oral Biol Med. 2000;11:259–74. https://doi.org/10.1177/10454411000110020801.
Hermsen MA, Riobello C, García-Marín R, Cabal VN, Suárez-Fernández L, López F, et al. Translational genomics of sinonasal cancers. Semin Cancer Biol. 2020;61:101–9. https://doi.org/10.1016/j.semcancer.2019.09.016.
Michel J, Fakhry N, Mancini J, Braustein D, Moreddu E, Giovanni A, et al. Sinonasal squamous cell carcinomas: clinical outcomes and predictive factors. Int J Oral Maxillofac Surg. 2014;43:1–6. https://doi.org/10.1016/j.ijom.2013.07.741.
•• Oliver JR, Lieberman SM, Tam MM, Liu CZ, Li Z, Hu KS, et al. Human papillomavirus and survival of patients with sinonasal squamous cell carcinoma. Cancer. 2020;126:1413–23. https://doi.org/10.1002/cncr.32679. This study contains a large retrospective NCDB cohort of SNSCC patients and reports noteworthy findings on the relationship between HPV status and SNSCC tumor characteristics, epidemiology, and survival.
Sanghvi S, Khan MN, Patel NR, Yeldandi S, Baredes S, Eloy JA. Epidemiology of sinonasal squamous cell carcinoma: a comprehensive analysis of 4994 patients. Laryngoscope. 2014;124:76–83. https://doi.org/10.1002/lary.24264.
Sjöstedt S, Jensen DH, Jakobsen KK, Grønhøj C, Geneser C, Karnov K, et al. Incidence and survival in sinonasal carcinoma: a Danish population-based, nationwide study from 1980 to 2014. Acta Oncol. 2018;57:1152–8. https://doi.org/10.1080/0284186X.2018.1454603.
Llorente JL, López F, Suárez C, Hermsen MA. Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances. Nat Rev Clin Oncol. 2014;11:460–72. https://doi.org/10.1038/nrclinonc.2014.97.
Takahashi Y, Bell D, Agarwal G, Roberts D, Xie T-X, El-Naggar A, et al. Comprehensive assessment of prognostic markers for sinonasal squamous cell carcinoma. Head Neck. 2014;36:1094–102. https://doi.org/10.1002/hed.23423.
Chowdhury N, Alvi S, Kimura K, Tawfik O, Manna P, Beahm D, et al. Outcomes of HPV-related nasal squamous cell carcinoma. Laryngoscope. 2017;127:1600–3. https://doi.org/10.1002/lary.26477.
Al-Qurayshi Z, Smith R, Walsh JE. Sinonasal squamous cell carcinoma presentation and outcome: a national perspective. Ann Otol Rhinol Laryngol. 2020;129:1049–55. https://doi.org/10.1177/0003489420929048.
Hongo T, Yamamoto H, Jiromaru R, Nozaki Y, Yasumatsu R, Hashimoto K, et al. Clinicopathologic significance of EGFR mutation and HPV infection in sinonasal squamous cell carcinoma. Am J Surg Pathol. 2021;45:108–18. https://doi.org/10.1097/PAS.0000000000001566.
Vazquez A, Khan MN, Blake DM, Patel TD, Baredes S, Eloy JA. Sinonasal squamous cell carcinoma and the prognostic implications of its histologic variants: a population-based study. Int Forum Allergy Rhinol. 2015;5:85–91. https://doi.org/10.1002/alr.21418.
Dhanani R, Faisal M, Shahid H, Malik KI, Jamshed A, Hussain R. Outcomes of management of sinonasal malignancies at a dedicated cancer institution: a retrospective study. Ann Maxillofac Surg. 2021;11:115–20. https://doi.org/10.4103/ams.ams_16_21.
Lee CH, Hur DG, Roh H-J, Rha K-S, Jin H-R, Rhee C-S, et al. Survival rates of sinonasal squamous cell carcinoma with the new AJCC staging system. Arch Otolaryngol Head Neck Surg. 2007;133:131–4. https://doi.org/10.1001/archotol.133.2.131.
Alos L, Moyano S, Nadal A, Alobid I, Blanch JL, Ayala E, et al. Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome. Cancer. 2009;115:2701–9. https://doi.org/10.1002/cncr.24309.
Hoffmann M, Klose N, Gottschlich S, Görögh T, Fazel A, Lohrey C, et al. Detection of human papillomavirus DNA in benign and malignant sinonasal neoplasms. Cancer Lett. 2006;239:64–70. https://doi.org/10.1016/j.canlet.2005.07.019.
Syrjänen K, Syrjänen S. Detection of human papillomavirus in sinonasal carcinoma: systematic review and meta-analysis. Hum Pathol. 2013;44:983–91. https://doi.org/10.1016/j.humpath.2012.08.017.
Laco J, Sieglová K, Vošmiková H, Dundr P, Němejcová K, Michálek J, et al. The presence of high-risk human papillomavirus (HPV) E6/E7 mRNA transcripts in a subset of sinonasal carcinomas is evidence of involvement of HPV in its etiopathogenesis. Virchows Arch. 2015;467:405–15. https://doi.org/10.1007/s00428-015-1812-x.
Rooper LM, Bishop JA, Westra WH. Transcriptionally active high-risk human papillomavirus is not a common etiologic agent in the malignant transformation of inverted schneiderian papillomas. Head Neck Pathol. 2017;11:346–53. https://doi.org/10.1007/s12105-017-0779-0.
Bishop JA, Ma X-J, Wang H, Luo Y, Illei PB, Begum S, et al. Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol. 2012;36:1874–82. https://doi.org/10.1097/PAS.0b013e318265fb2b.
• Jiromaru R, Yamamoto H, Yasumatsu R, Hongo T, Nozaki Y, Hashimoto K, et al. HPV-related sinonasal carcinoma: clinicopathologic features, diagnostic utility of p16 and Rb immunohistochemistry, and EGFR copy number alteration. Am J Surg Pathol. 2020;44:305–15. https://doi.org/10.1097/PAS.0000000000001410. This retrospective study reports favorable survival outcomes for SNSCC patients with HPV-positive lesions and importantly calls into question the use of p16 staining as a surrogate marker for HPV infection in SNSCC.
Larque AB, Hakim S, Ordi J, Nadal A, Diaz A, del Pino M, et al. High-risk human papillomavirus is transcriptionally active in a subset of sinonasal squamous cell carcinomas. Mod Pathol. 2014;27:343–51. https://doi.org/10.1038/modpathol.2013.155.
Schlussel Markovic E, Marqueen KE, Sindhu KK, Lehrer EJ, Liu J, Miles B, et al. The prognostic significance of human papilloma virus in sinonasal squamous cell carcinoma. Laryngoscope Investig Otolaryngol. 2020;5:1070–8. https://doi.org/10.1002/lio2.468.
Kılıç S, Kılıç SS, Kim ES, Baredes S, Mahmoud O, Gray ST, et al. Significance of human papillomavirus positivity in sinonasal squamous cell carcinoma. Int Forum Allergy Rhinol. 2017;7:980–9. https://doi.org/10.1002/alr.21996.
Ansa B, Goodman M, Ward K, Kono SA, Owonikoko TK, Higgins K, et al. Paranasal sinus squamous cell carcinoma incidence and survival based on surveillance, epidemiology, and end results data, 1973 to 2009. Cancer. 2013;119:2602–10. https://doi.org/10.1002/cncr.28108.
Bauwens L, Baltres A, Fiani D-J, Zrounba P, Buiret G, Fleury B, et al. Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma. Radiother Oncol. 2021;157:122–9. https://doi.org/10.1016/j.radonc.2021.01.028.
Carpén T, Sjöblom A, Lundberg M, Haglund C, Markkola A, Syrjänen S, et al. Presenting symptoms and clinical findings in HPV-positive and HPV-negative oropharyngeal cancer patients. Acta Otolaryngol. 2018;138:513–8. https://doi.org/10.1080/00016489.2017.1405279.
El-Mofty SK, Lu DW. Prevalence of high-risk human papillomavirus DNA in nonkeratinizing (cylindrical cell) carcinoma of the sinonasal tract: a distinct clinicopathologic and molecular disease entity. Am J Surg Pathol. 2005;29:1367–72. https://doi.org/10.1097/01.pas.0000173240.63073.fe.
Lewis JS. Sinonasal squamous cell carcinoma: a review with emphasis on emerging histologic subtypes and the role of human papillomavirus. Head Neck Pathol. 2016;10:60–7. https://doi.org/10.1007/s12105-016-0692-y.
Chernock RD, El-Mofty SK, Thorstad WL, Parvin CA, Lewis JS. HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol. 2009;3:186–94. https://doi.org/10.1007/s12105-009-0126-1.
Klussmann JP, Gültekin E, Weissenborn SJ, Wieland U, Dries V, Dienes HP, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol. 2003;162:747–53. https://doi.org/10.1016/S0002-9440(10)63871-0.
•• Udager AM, McHugh JB, Goudsmit CM, Weigelin HC, Lim MS, Elenitoba-Johnson KSJ, et al. Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas. Ann Oncol. 2018;29:466–71. https://doi.org/10.1093/annonc/mdx736. This study demonstrated that all IP and IP-SNSCC harbored the presence of either HPV or an EGFR mutation, suggesting that HPV transduction and EGFR mutations represent alternate, mutually exclusive, pathways in IP.
Lawson W, Schlecht NF, Brandwein-Gensler M. The role of the human papillomavirus in the pathogenesis of Schneiderian inverted papillomas: an analytic overview of the evidence. Head Neck Pathol. 2008;2:49–59. https://doi.org/10.1007/s12105-008-0048-3.
• Sharma A, Tang AL, Takiar V, Wise-Draper TM, Langevin SM. Human papillomavirus and survival of sinonasal squamous cell carcinoma patients: a systematic review and meta-analysis. Cancers (Basel). 2021;13:3677. https://doi.org/10.3390/cancers13153677. This recently published meta-analysis synthesized data from all studies in the SNSCC literature that reported survival outcomes stratified by HPV status. Their findings demonstrate a significant association between HPV status and overall survival.
Jenko K, Kocjan B, Zidar N, Poljak M, Strojan P, Zargi M, et al. In inverted papillomas HPV more likely represents incidental colonization than an etiological factor. Virchows Arch. 2011;459:529–38. https://doi.org/10.1007/s00428-011-1139-1.
Lesperance MM, Esclamado RM. Squamous cell carcinoma arising in inverted papilloma. Laryngoscope. 1995;105:178–83. https://doi.org/10.1288/00005537-199502000-00013.
Nudell J, Chiosea S, Thompson LDR. Carcinoma ex-Schneiderian papilloma (malignant transformation): a clinicopathologic and immunophenotypic study of 20 cases combined with a comprehensive review of the literature. Head Neck Pathol. 2014;8:269–86. https://doi.org/10.1007/s12105-014-0527-7.
Re M, Gioacchini FM, Bajraktari A, Tomasetti M, Kaleci S, Rubini C, et al. Malignant transformation of sinonasal inverted papilloma and related genetic alterations: a systematic review. Eur Arch Otorhinolaryngol. 2017;274:2991–3000. https://doi.org/10.1007/s00405-017-4571-2.
Barnes L. Schneiderian papillomas and nonsalivary glandular neoplasms of the head and neck. Mod Pathol. 2002;15:279–97. https://doi.org/10.1038/modpathol.3880524.
Li Y, Wang C, Wang R, Zhang J, Liu H, Shi Q, et al. Prognostic factors of sinonasal squamous cell carcinomas arising de novo and from inverted papilloma. Am J Rhinol Allergy. 2021;35:114–21. https://doi.org/10.1177/1945892420939422.
Syrjänen K, Syrjänen S. Detection of human papillomavirus in sinonasal papillomas: systematic review and meta-analysis. Laryngoscope. 2013;123:181–92. https://doi.org/10.1002/lary.23688.
Syrjänen KJ. HPV infections in benign and malignant sinonasal lesions. J Clin Pathol. 2003;56:174–81. https://doi.org/10.1136/jcp.56.3.174.
Pähler Vor der Holte A, Fangk I, Glombitza S, Wilkens L, Welkoborsky HJ. Prognostic factors and risk factors for development and recurrence of sinonasal papillomas: potential role of different HPV subtypes. Eur Arch Otorhinolaryngol 2020;277:767–75. https://doi.org/10.1007/s00405-019-05747-4.
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–25. https://doi.org/10.1038/nature11404.
Udager AM, McHugh JB, Elenitoba-Johnson KSJ, Brown NA. EGFR mutations in sinonasal squamous tumors: oncogenic and therapeutic implications. Oncoscience 2015;2:908–9. https://doi.org/10.18632/oncoscience.268.
Liu Y, Duan L, Tian J, Song D, Zhang M, Zhao S, et al. Role of the Akt/mTOR signaling pathway in human papillomavirus-associated nasal and sinonasal inverted papilloma. Acta Biochim Biophys Sin (Shanghai). 2017;49:1067–74. https://doi.org/10.1093/abbs/gmx108.
Paehler Vor der Holte A, Fangk I, Glombitza S, Wilkens L, Welkoborsky HJ. Impact of human papillomaviruses (HPV) on recurrence rate and malignant progression of sinonasal papillomas. Cancer Med 2021;10:634–41. https://doi.org/10.1002/cam4.3642.
Ding R, Sun Q, Wang Y. Association between human papilloma virus infection and malignant sinonasal inverted papilloma. Laryngoscope. 2021;131:1200–5. https://doi.org/10.1002/lary.29125.
• Stepp WH, Farzal Z, Kimple AJ, Ebert CS, Senior BA, Zanation AM, et al. HPV in the malignant transformation of sinonasal inverted papillomas: a meta-analysis. Int Forum Allergy Rhinol. 2021;11(10):1461–71. https://doi.org/10.1002/alr.22810. This meta-analysis of 19 studies investigated the association between HPV presence and risk of malignant transformation from inverted papilloma to squamous cell carcinoma. They report a positive significant association between these, and they suggest a possible role for HPV testing of surgically resected inverted papillomas in guiding oncologic surveillance.
Syrjänen S, Syrjänen K. HPV-associated benign squamous cell papillomas in the upper aero-digestive tract and their malignant potential. Viruses. 2021;13:1624. https://doi.org/10.3390/v13081624.
McCormick JP, Suh JD, Lee JT, Wells C, Wang MB. Role of high-risk hpv detected by pcr in malignant sinonasal inverted papilloma: a meta-analysis. Laryngoscope 2021. Online ahead of print. https://doi.org/10.1002/lary.29735.
Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma. Cancer. 2017;123:1778–90. https://doi.org/10.1002/cncr.30570.
Mehrad M, Stelow EB, Bishop JA, Wang X, Haynes W, Oliver D, et al. Transcriptionally active HPV and targetable EGFR mutations in sinonasal inverted papilloma: an association between low-risk HPV, condylomatous morphology, and cancer risk? Am J Surg Pathol. 2020;44:340–6. https://doi.org/10.1097/PAS.0000000000001411.
Udager AM, Rolland DCM, McHugh JB, Betz BL, Murga-Zamalloa C, Carey TE, et al. High-frequency targetable EGFR mutations in sinonasal squamous cell carcinomas arising from inverted sinonasal papilloma. Cancer Res. 2015;75:2600–6. https://doi.org/10.1158/0008-5472.CAN-15-0340.
Cabal VN, Menendez M, Vivanco B, Potes-Ares S, Riobello C, Suarez-Fernandez L, et al. EGFR mutation and HPV infection in sinonasal inverted papilloma and squamous cell carcinoma. Rhinology. 2020;58:368–76. https://doi.org/10.4193/Rhin19.371.
Brown NA, Plouffe KR, Yilmaz O, Weindorf SC, Betz BL, Carey TE, et al. TP53 mutations and CDKN2A mutations/deletions are highly recurrent molecular alterations in the malignant progression of sinonasal papillomas. Mod Pathol. 2021;34:1133–42. https://doi.org/10.1038/s41379-020-00716-3.
Bishop JA, Westra WH. Human papillomavirus-related multiphenotypic sinonasal carcinoma: an emerging tumor type with a unique microscopic appearance and a paradoxical clinical behaviour. Oral Oncol. 2018;87:17–20. https://doi.org/10.1016/j.oraloncology.2018.10.011.
•• Zupancic M, Näsman A. Human papillomavirus-related multiphenotypic sinonasal carcinoma-an even broader tumor entity? Viruses. 2021;13:1861. https://doi.org/10.3390/v13091861. This is the first systematic review published of all HPV-related multiphenotypic sinonasal carcinomas diagnosed after the first case report in 2013. It offers insight into the tumor’s clinicopathologic characteristics and its relation to HPV.
Chen C-C, Yang S-F. Human papillomavirus-related carcinoma with adenoid cystic-like features of the sinonasal tract (also known as human papillomavirus-related multiphenotypic sinonasal carcinoma). Arch Pathol Lab Med. 2019;143:1420–4. https://doi.org/10.5858/arpa.2018-0027-RS.
El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ (eds). World Health Organization Classification of Head and Neck Tumours. 4th ed. Lyon: IARC. 2017.
Bishop JA, Ogawa T, Stelow EB, Moskaluk CA, Koch WM, Pai SI, et al. Human papillomavirus-related carcinoma with adenoid cystic-like features: a peculiar variant of head and neck cancer restricted to the sinonasal tract. Am J Surg Pathol. 2013;37:836–44. https://doi.org/10.1097/PAS.0b013e31827b1cd6.
Thompson LDR. HPV-related multiphenotypic sinonasal carcinoma. Ear Nose Throat J. 2020;99:94–5. https://doi.org/10.1177/0145561319871711.
• Ward ML, Kernig M, Willson TJ. HPV-related multiphenotypic sinonasal carcinoma: a case report and literature review. Laryngoscope. 2021;131:106–10. https://doi.org/10.1002/lary.28598. This case report and literature review spanning between 2000-2018 provides useful information on tumor staging, recurrence and metastasis rates, and survival following radiotherapy in HPV-related multiphenotypic sinonasal carcinoma.
• Rupp NJ, Camenisch U, Seidl K, Rushing EJ, Anderegg N, Broglie MA, et al. HPV-related multiphenotypic sinonasal carcinoma: four cases that expand the morpho-molecular spectrum and include occupational data. Head Neck Pathol. 2020;14:623–9. https://doi.org/10.1007/s12105-019-01079-1. This case series reported four HPV-related multiphenotypic sinonasal carcinomas, and interestingly, noted that three afflicted patients were nurses or nursing assistants, sparking discussion regarding a possible occupational association to this sinonasal tumor type and unveiling a need for future epidemiologic studies.
Bishop JA, Andreasen S, Hang J-F, Bullock MJ, Chen TY, Franchi A, et al. HPV-related multiphenotypic sinonasal carcinoma: an expanded series of 49 cases of the tumor formerly known as HPV-related carcinoma with adenoid cystic carcinoma-like features. Am J Surg Pathol. 2017;41:1690–701. https://doi.org/10.1097/PAS.0000000000000944.
Antony VM, Kakkar A, Sikka K, Thakar A, Deo SVS, Bishop JA, et al. p16 Immunoexpression in sinonasal and nasopharyngeal adenoid cystic carcinomas: a potential pitfall in ruling out HPV-related multiphenotypic sinonasal carcinoma. Histopathology. 2020;77:989–93. https://doi.org/10.1111/his.14212.
Hsieh M-S, Lee Y-H, Jin Y-T, Huang W-C. Strong SOX10 expression in human papillomavirus-related multiphenotypic sinonasal carcinoma: report of 6 new cases validated by high-risk human papillomavirus mRNA in situ hybridization test. Hum Pathol. 2018;82:264–72. https://doi.org/10.1016/j.humpath.2018.07.026.
de Villiers E-M, Fauquet C, Broker TR, Bernard H-U. zur Hausen H. Classification of papillomaviruses Virology. 2004;324:17–27. https://doi.org/10.1016/j.virol.2004.03.033.
•• Baraban E, Tong CCL, Adappa ND, Cooper K. A subset of sinonasal undifferentiated carcinoma is associated with transcriptionally active high-risk human papillomavirus by in situ hybridization: a clinical and pathologic analysis. Hum Pathol. 2020;101:64–9. https://doi.org/10.1016/j.humpath.2020.05.002. This retrospective study put forth the largest SNUC case series yet appraised for HPV. Findings demonstrate a 20% rate of transcriptionally active high-risk HPV positivity in SNUC along with a lack of statistically significant association between high-risk HPV and overall survival.
Tyler MA, Holmes B, Patel ZM. Oncologic management of sinonasal undifferentiated carcinoma. Curr Opin Otolaryngol Head Neck Surg. 2019;27:59–66. https://doi.org/10.1097/MOO.0000000000000513.
Lewis JS, Bishop JA, Gillison M, Westra WH, Yarbrough WG. Sinonasal undifferentiated carcinoma. WHO Classification of Head and Neck Tumours 2017:18–20.
Al-Mamgani A, van Rooij P, Mehilal R, Tans L, Levendag PC. Combined-modality treatment improved outcome in sinonasal undifferentiated carcinoma: single-institutional experience of 21 patients and review of the literature. Eur Arch Otorhinolaryngol. 2013;270:293–9. https://doi.org/10.1007/s00405-012-2008-5.
Musy PY, Reibel JF, Levine PA. Sinonasal undifferentiated carcinoma: the search for a better outcome. Laryngoscope. 2002;112:1450–5. https://doi.org/10.1097/00005537-200208000-00023.
Reiersen DA, Pahilan ME, Devaiah AK. Meta-analysis of treatment outcomes for sinonasal undifferentiated carcinoma. Otolaryngol Head Neck Surg. 2012;147:7–14. https://doi.org/10.1177/0194599812440932.
Chambers KJ, Lehmann AE, Remenschneider A, Dedmon M, Meier J, Gray ST, et al. Incidence and survival patterns of sinonasal undifferentiated carcinoma in the United States. J Neurol Surg B Skull Base. 2015;76:94–100. https://doi.org/10.1055/s-0034-1390016.
Glöss S, Jurmeister P, Thieme A, Schmid S, Cai WY, Serrette RN, et al. IDH2 R172 mutations across poorly differentiated sinonasal tract malignancies: forty molecularly homogenous and histologically variable cases with favorable outcome. Am J Surg Pathol. 2021;45:1190–204. https://doi.org/10.1097/PAS.0000000000001697.
Chitguppi C, Rabinowitz MR, Johnson J, Bar-Ad V, Fastenberg JH, Molligan J, et al. Loss of SMARCB1 expression confers poor prognosis to sinonasal undifferentiated carcinoma. J Neurol Surg B Skull Base. 2020;81:610–9. https://doi.org/10.1055/s-0039-1693659.
Lopez DC, Wadley AE, London NR. Emerging concepts in sinonasal tumor research. Curr Opin Otolaryngol Head Neck Surg. 2022;30:33–9. https://doi.org/10.1097/MOO.0000000000000776.
Gray ST, Herr MW, Sethi RKV, Diercks G, Lee L, Curry W, et al. Treatment outcomes and prognostic factors, including human papillomavirus, for sinonasal undifferentiated carcinoma: a retrospective review. Head Neck. 2015;37:366–74. https://doi.org/10.1002/hed.23606.
Wadsworth B, Bumpous JM, Martin AW, Nowacki MR, Jenson AB, Farghaly H. Expression of p16 in sinonasal undifferentiated carcinoma (SNUC) without associated human papillomavirus (HPV). Head and Neck Pathol. 2011;5:349–54. https://doi.org/10.1007/s12105-011-0285-8.
Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet. 2016;387:1012–24. https://doi.org/10.1016/S0140-6736(15)00055-0.
• Verma N, Patel S, Osborn V, McBride S, Riaz N, Lee A, et al. Prognostic significance of human papillomavirus and Epstein-Bar virus in nasopharyngeal carcinoma. Head Neck. 2020;42:2364–74. https://doi.org/10.1002/hed.26245. This retrospective review of nasopharyngeal carcinoma offered evidence to suggest that neither EBV nor HPV viral status was prognostic for overall survival, time to local failure, or time to distant metastases in 343 patients diagnosed between 1998-2017.
Guo X, Johnson RC, Deng H, Liao J, Guan L, Nelson GW, et al. Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. Int J Cancer. 2009;124:2942–7. https://doi.org/10.1002/ijc.24293.
Jia W-H, Huang Q-H, Liao J, Ye W, Shugart Y, Liu Q, et al. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20–25 year period (1978/1983–2002) in Sihui and Cangwu counties in southern China. BMC Cancer. 2006;6:178. https://doi.org/10.1186/1471-2407-6-178.
•• Ruuskanen M, Irjala H, Minn H, Vahlberg T, Randen-Brady R, Hagström J, et al. Epstein-Barr virus and human papillomaviruses as favorable prognostic factors in nasopharyngeal carcinoma: a nationwide study in Finland. Head Neck. 2019;41:349–57. https://doi.org/10.1002/hed.25450. This 2019 whole population study out of Finland, a nonendemic region, evaluated samples from 150 patients and found that 5-year disease specific survival is significantly better for both EBV and HPV positive nasopharyngeal carcinoma than for EBV/HPV double negative nasopharyngeal carcinoma.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-386. https://doi.org/10.1002/ijc.29210.
Xu F-H, Xiong D, Xu Y-F, Cao S-M, Xue W-Q, Qin H-D, et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J Natl Cancer Inst. 2012;104:1396–410. https://doi.org/10.1093/jnci/djs320.
Yeo ELL, Li YQ, Soo K-C, Wee JTS, Chua MLK. Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma. Chin Clin Oncol 2018;7:15. https://doi.org/10.21037/cco.2018.04.05.
Lee AWM, Ng WT, Chan JYW, Corry J, Mäkitie A, Mendenhall WM, et al. Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev. 2019;79: 101890. https://doi.org/10.1016/j.ctrv.2019.101890.
Huang WB, Chan JYW, Liu DL. Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: multicenter study from an endemic area in Southern China. Cancer. 2018;124:530–6. https://doi.org/10.1002/cncr.31031.
Tham T, Machado R, Russo DP, Herman SW, Teegala S, Costantino P. Viral markers in nasopharyngeal carcinoma: a systematic review and meta-analysis on the detection of p16INK4a, human papillomavirus (HPV), and Ebstein-Barr virus (EBV). Am J Otolaryngol. 2021;42: 102762. https://doi.org/10.1016/j.amjoto.2020.102762.
Simon J, Schroeder L, Ingarfield K, Diehl S, Werner J, Brenner N, et al. Epstein-Barr virus and human papillomavirus serum antibodies define the viral status of nasopharyngeal carcinoma in a low endemic country. Int J Cancer. 2020;147:461–71. https://doi.org/10.1002/ijc.33006.
•• Wotman M, Oh EJ, Ahn S, Kraus D, Costantino P, Tham T. HPV status in patients with nasopharyngeal carcinoma in the United States: a SEER database study. Am J Otolaryngol. 2019;40:705–10. https://doi.org/10.1016/j.amjoto.2019.06.007. This review of U.S. SEER database nasopharyngeal carcinoma cases demonstrated that positive HPV status is associated with improved cause-specific survival in East Asian individuals but worse cause-specific survival in Caucasian individuals. This study draws attention to the potentially important impact of ethnicity on HPV’s role in nasopharyngeal carcinoma survival.
Robinson M, Suh Y-E, Paleri V, Devlin D, Ayaz B, Pertl L, et al. Oncogenic human papillomavirus-associated nasopharyngeal carcinoma: an observational study of correlation with ethnicity, histological subtype and outcome in a UK population. Infect Agent Cancer. 2013;8:30. https://doi.org/10.1186/1750-9378-8-30.
Singhi AD, Califano J, Westra W. High-risk human papillomavirus in nasopharyngeal carcinoma. Head Neck. 2012;34:213–8. https://doi.org/10.1002/hed.21714.
Atighechi S, Ahmadpour Baghdadabad MR, Mirvakili SA, Sheikhha MH, Baradaranfar MH, Dadgarnia MH, et al. Human papilloma virus and nasopharyngeal carcinoma: pathology, prognosis, recurrence and mortality of the disease. Exp Oncol. 2014;36:215–6.
Dogan S, Hedberg ML, Ferris RL, Rath TJ, Assaad AM, Chiosea SI. Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. Head Neck. 2014;36:511–6. https://doi.org/10.1002/hed.23318.
Tham T, Teegala S, Bardash Y, Herman SW, Costantino P. Is human papillomavirus and p16 expression associated with survival outcomes in nasopharyngeal cancer?: A systematic review and meta-analysis. Am J Otolaryngol. 2018;39:764–70. https://doi.org/10.1016/j.amjoto.2018.07.005.
• Feng G, Xu Y, Ma N, Midorikawa K, Oikawa S, Kobayashi H, et al. Influence of Epstein-Barr virus and human papillomavirus infection on macrophage migration inhibitory factor and macrophage polarization in nasopharyngeal carcinoma. BMC Cancer. 2021;21:929. https://doi.org/10.1186/s12885-021-08675-x. This study aimed to understand the impact of EBV and HPV on the activated tumor environment of nasopharyngeal carcinoma with immunofluorescence staining. It demonstrated that EBV infection may promote macrophage inhibitory factor production while tumoricidal macrophage infiltration may be affected by HPV presence.
Chen Y-P, Lv J-W, Mao Y-P, Li X-M, Li J-Y, Wang Y-Q, et al. Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. Mol Cancer. 2021;20:14. https://doi.org/10.1186/s12943-020-01292-5.
Medrek C, Pontén F, Jirström K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;12:306. https://doi.org/10.1186/1471-2407-12-306.
Kindt N, Journe F, Laurent G, Saussez S. Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets. Oncol Lett. 2016;12:2247–53. https://doi.org/10.3892/ol.2016.4929.
Lechien JR, Nassri A, Kindt N, Brown DN, Journe F, Saussez S. Role of macrophage migration inhibitory factor in head and neck cancer and novel therapeutic targets: a systematic review. Head Neck. 2017;39:2573–84. https://doi.org/10.1002/hed.24939.
Hsu C, Lee S-H, Ejadi S, Even C, Cohen RB, Le Tourneau C, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017;35:4050–6. https://doi.org/10.1200/JCO.2017.73.3675.
Ma BBY, Lim W-T, Goh B-C, Hui EP, Lo K-W, Pettinger A, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018;36:1412–8. https://doi.org/10.1200/JCO.2017.77.0388.
Delord J-P, Hollebecque A, De Boer JP, De Greve J, Machiels J-PH, Leidner RS, et al. An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC). JCO 2017;35:6025–6025. https://doi.org/10.1200/JCO.2017.35.15_suppl.6025.
Mai H-Q, Chen Q-Y, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021;27:1536–43. https://doi.org/10.1038/s41591-021-01444-0.
Zhu Q-Y, Zhao G-X, Li Y, Talakatta G, Mai H-Q, Le Q-T, et al. Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma. MedComm. 2020;2021(2):175–206. https://doi.org/10.1002/mco2.32.
Uddin MN, Henry B, Carter KD, Roni MA, Kouzi SS. A novel formulation strategy to deliver combined DNA and VLP based HPV vaccine. J Pharm Pharm Sci 2019;22:536–47. https://doi.org/10.18433/jpps30768.
Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Harjula K, et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials. BMJ Open. 2017;7: e015867. https://doi.org/10.1136/bmjopen-2017-015867.